2026-06-25

Silver volume spike — 6.3× the 20-day average (573 vs 90 avg)

Platinum volume spike — 5.1× the 20-day average (61 vs 11 avg)

OSINT: US Supreme Court Blocks Roundup Cancer Lawsuits, Shields Bayer

Cocoa bull 6.7% vs prior close ($4,902.00 → $5,230.00)

Cotton bull 6.3% vs prior close ($72.09 → $76.61)

CFTC COPPER speculators at extreme long: 52-week positioning extreme

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

OSINT: US Investor Confidence Falls to 25%, Down from 34% Last Quarter

CFTC COPPER speculators at extreme long: 52-week positioning extreme

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

OSINT: Saudi Arabia oil output update draws market attention

CFTC COPPER speculators at extreme long: 52-week positioning extreme

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

OSINT: Iran-linked wallets shift $3.84B via CoinEx, including Revolutionary Guard funds

CFTC COPPER speculators at extreme long: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

Oil -5.12%: significant decline on the session

Cocoa volume spike — 2.2× the 20-day average (28,502 vs 13,134 avg)

Sugar No. 11 bull 5.2% vs prior close ($13.42 → $14.12)

Soybeans bull 4.4% vs prior close ($1,108.75 → $1,157.50)

Coffee bear 5.1% vs prior close ($291.55 → $276.75)

Corn bull 4.2% vs prior close ($407.00 → $424.25)

Phase 3 trial terminated early — JOHNSON A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Pati

Phase 3 trial terminated early — BIOGEN A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants Wit

Phase 3 trial terminated early — AMGEN Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or M

Phase 3 trial terminated early — AMGEN Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects

Phase 3 trial terminated early — Merck Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppress

Phase 3 trial terminated early — Merck MK0767 and Sulfonylurea Combination Study (0767-027)

Phase 3 trial terminated early — Merck Long-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis

Phase 3 trial terminated early — PFIZER Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized A

Phase 3 trial terminated early — PFIZER Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For

Phase 3 trial terminated early — PFIZER Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atr

Phase 3 trial terminated early — PFIZER Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infect

Phase 3 trial terminated early — PFIZER A Clinical Trial Assessing The Impact Of Inhaled Insulin On Glucose Control In P

Phase 3 trial terminated early — PFIZER An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Toler

Phase 3 trial terminated early — PFIZER Phase III Acute Coronary Syndrome

Phase 3 trial terminated early — ABBOTT Evaluation of an Oral Nutritional Supplement in Older Hospitalized Patients

Phase 3 trial terminated early — ABBOTT Study of Trilipix Effects on Lipids and Arteries

Phase 3 trial terminated early — GILEAD Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to N

Phase 3 trial terminated early — GILEAD Roll Over Study to Provide Idelalisib to Participants Previously Treated With th

Phase 3 trial terminated early — GILEAD ANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monothe

Phase 3 trial terminated early — GILEAD Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously

Phase 3 trial terminated early — GILEAD Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of E

BITCOIN — speculators net long (+2.5σ vs 52w mean) — contrarian bear signal

Activist 13D filing — engage in discussions

CVS HEALTH Corp search volume spiked +88 pts — unusual interest

Sanofi search volume spiked +37 pts — unusual interest

Q1-2026: Beat consensus by 24.4% — EPS $0.85 vs $0.6831 estimate

Q3-2025: Missed consensus by 19.9% — EPS $0.54 vs $0.6738 estimate

Q2-2025: Missed consensus by 11.0% — EPS $0.62 vs $0.6963 estimate

Q2-2025: Beat consensus by 7.9% — EPS $1.26 vs $1.1675 estimate

Q3-2025: Beat consensus by 10.0% — EPS $1.37 vs $1.2452 estimate

Q4-2019: Missed consensus by 11.1% — EPS $0.3 vs $0.3376 estimate

Q3-2019: Missed consensus by 36.3% — EPS $0.45 vs $0.7066 estimate

Q1-2020: Missed consensus by 246.7% — EPS $-0.42 vs $0.2863 estimate

Q2-2019: Beat consensus by 35.1% — EPS $0.93 vs $0.6882 estimate

Q2-2025: Missed consensus by 114.9% — EPS $-4083 vs $-1900.26 estimate

Q3-2025: Missed consensus by 42.4% — EPS $-318 vs $-223.38 estimate

Q1-2026: Missed consensus by 322.0% — EPS $-361.6 vs $-85.68 estimate

Q4-2025: Beat consensus by 98.8% — EPS $-1.8 vs $-149.94 estimate

Q3-2023: Missed consensus by 191.7% — EPS $-2.38 vs $-0.816 estimate

Q4-2022: Missed consensus by 83.8% — EPS $-3 vs $-1.632 estimate

Q1-2023: Beat consensus by 47.2% — EPS $-1.4 vs $-2.652 estimate

Q3-2025: Missed consensus by 96.1% — EPS $-0.02 vs $-0.0102 estimate

Q3-2025: Beat consensus by 296.1% — EPS $0.01 vs $-0.0051 estimate

Q2-2025: Beat consensus by 296.1% — EPS $0.02 vs $-0.0102 estimate

Q1-2026: Missed consensus by 17.6% — EPS $-0.02 vs $-0.017 estimate

Q4-2025: Beat consensus by 100.0% — EPS $0 vs $-0.0051 estimate

Q3-2025: Missed consensus by 86.9% — EPS $-0.61 vs $-0.3264 estimate

Q1-2026: Missed consensus by 366.9% — EPS $-1 vs $-0.2142 estimate

Q2-2025: Missed consensus by 59.6% — EPS $-2.36 vs $-1.479 estimate

Q4-2025: Missed consensus by 416.1% — EPS $-1.79 vs $-0.3468 estimate

Q3-2025: Beat consensus by 59.7% — EPS $0.2 vs $0.1252 estimate

Q1-2026: Missed consensus by 55.7% — EPS $-0.43 vs $-0.2761 estimate

Q4-2025: Missed consensus by 199.0% — EPS $-0.1 vs $0.101 estimate

Q2-2025: Missed consensus by 892.1% — EPS $-0.64 vs $0.0808 estimate

Q2-2023: Beat consensus by 52.1% — EPS $-5.445 vs $-11.3625 estimate

Q4-2022: Beat consensus by 26.7% — EPS $-9 vs $-12.2715 estimate

Q1-2023: Beat consensus by 52.6% — EPS $-4.95 vs $-10.4535 estimate

Q1-2024: Missed consensus by 372.2% — EPS $-1.24 vs $-0.2626 estimate

Q2-2025: Missed consensus by 133.0% — EPS $-0.05 vs $0.1515 estimate

Q3-2025: Missed consensus by 57.5% — EPS $0.02 vs $0.0471 estimate

Q1-2026: Missed consensus by 694.1% — EPS $-0.06 vs $0.0101 estimate

Q4-2025: Missed consensus by 937.1% — EPS $-0.55 vs $0.0657 estimate

Q1-2026: Missed consensus by 5.3% — EPS $0.27 vs $0.285 estimate

Q3-2025: Missed consensus by 19.0% — EPS $0.37 vs $0.457 estimate

Q1-2026: Missed consensus by 10.5% — EPS $0.09 vs $0.1006 estimate

Q4-2025: Missed consensus by 17.3% — EPS $0.21 vs $0.254 estimate

Q2-2025: Beat consensus by 52.7% — EPS $0.3 vs $0.1964 estimate

Q1-2024: Missed consensus by 12.6% — EPS $-31 vs $-27.54 estimate

Q2-2025: Beat consensus by 30.7% — EPS $-0.41 vs $-0.5916 estimate

Q2-2024: Missed consensus by 8.9% — EPS $-30 vs $-27.54 estimate

Q3-2024: Missed consensus by 20.3% — EPS $-24.55 vs $-20.4 estimate

Q4-2025: Missed consensus by 4017.6% — EPS $-0.91 vs $-0.0221 estimate

Q2-2025: Beat consensus by 16.6% — EPS $0.26 vs $0.2229 estimate

Q3-2025: Beat consensus by 172.0% — EPS $0.34 vs $0.125 estimate

Q1-2026: Missed consensus by 135.7% — EPS $-0.04 vs $0.1122 estimate

Q1-2026: Beat consensus by 14.1% — EPS $1.01 vs $0.8851 estimate

Q4-2025: Beat consensus by 13.4% — EPS $0.88 vs $0.7762 estimate

Q4-2025: Beat consensus by 100.0% — EPS $0 vs $-0.0101 estimate

Q2-2025: Beat consensus by 50.5% — EPS $-0.01 vs $-0.0202 estimate

Q3-2025: Missed consensus by 98.0% — EPS $-0.02 vs $-0.0101 estimate

Q1-2026: Missed consensus by 89.7% — EPS $-1.86 vs $-0.9806 estimate

Q4-2025: Beat consensus by 220.5% — EPS $0.4 vs $-0.3319 estimate

Q2-2025: Beat consensus by 34.8% — EPS $-0.5 vs $-0.767 estimate

Q1-2026: Beat consensus by 82.8% — EPS $0.23 vs $0.1258 estimate

Q4-2025: Beat consensus by 8.5% — EPS $0.24 vs $0.2213 estimate

Q2-2025: Beat consensus by 13.9% — EPS $0.11 vs $0.0966 estimate

Q3-2025: Beat consensus by 31.3% — EPS $0.28 vs $0.2132 estimate

Q3-2025: Missed consensus by 10.8% — EPS $0.47 vs $0.527 estimate

Q4-2025: Beat consensus by 7.4% — EPS $0.49 vs $0.4563 estimate

Q2-2025: Beat consensus by 10.0% — EPS $0.59 vs $0.5365 estimate

Q1-2026: Missed consensus by 5.6% — EPS $2.49 vs $2.637 estimate

Q1-2026: Beat consensus by 40.5% — EPS $-0.43 vs $-0.7222 estimate

Q4-2025: Missed consensus by 32.0% — EPS $-0.9 vs $-0.6818 estimate

Q3-2025: Beat consensus by 16.4% — EPS $-0.74 vs $-0.8854 estimate

Q2-2025: Beat consensus by 15.3% — EPS $-0.91 vs $-1.074 estimate

Q1-2026: Missed consensus by 117.3% — EPS $-0.03 vs $0.1734 estimate

Q4-2025: Beat consensus by 264.5% — EPS $0.26 vs $-0.1581 estimate

Q2-2025: Beat consensus by 295.5% — EPS $0.44 vs $-0.2251 estimate

Q3-2025: Beat consensus by 1815.7% — EPS $0.7 vs $-0.0408 estimate

Q1-2026: Beat consensus by 14.3% — EPS $1.16 vs $1.015 estimate

Q2-2025: Beat consensus by 5.1% — EPS $1.64 vs $1.5599 estimate

Q1-2026: Missed consensus by 186.7% — EPS $-0.32 vs $-0.1116 estimate

Q1-2026: Missed consensus by 117.5% — EPS $-1.71 vs $-0.7862 estimate

Q2-2025: Beat consensus by 44.2% — EPS $-0.41 vs $-0.7347 estimate

Q3-2025: Beat consensus by 88.6% — EPS $-0.08 vs $-0.7021 estimate

Q4-2025: Beat consensus by 85.4% — EPS $-0.09 vs $-0.6152 estimate

Q4-2025: Beat consensus by 42.3% — EPS $0.16 vs $0.1124 estimate

Q2-2025: Beat consensus by 96.5% — EPS $0.09 vs $0.0458 estimate

Q1-2026: Beat consensus by 13.9% — EPS $0.12 vs $0.1054 estimate

Q2-2025: Missed consensus by 98.0% — EPS $-2.24 vs $-1.1312 estimate

Q1-2026: Beat consensus by 13.0% — EPS $-0.58 vs $-0.6666 estimate

Q3-2025: Beat consensus by 80.2% — EPS $-0.084 vs $-0.4242 estimate

Q4-2025: Beat consensus by 147.7% — EPS $0.81 vs $-1.6968 estimate

Q3-2020: Missed consensus by 31.0% — EPS $4.6 vs $6.666 estimate

Q4-2011: Beat consensus by 14.0% — EPS $3.8 vs $3.333 estimate

Q2-2012: Beat consensus by 132.7% — EPS $9.4 vs $4.04 estimate

Q1-2012: Beat consensus by 22.8% — EPS $3.1 vs $2.525 estimate

Q4-2025: Missed consensus by 79.4% — EPS $0.3 vs $1.4581 estimate

Q1-2026: Beat consensus by 357.5% — EPS $0.35 vs $0.0765 estimate

Q3-2025: Missed consensus by 242.6% — EPS $-0.4 vs $0.2805 estimate

Q2-2025: Beat consensus by 81.8% — EPS $0.56 vs $0.3081 estimate

Q1-2026: Beat consensus by 15.5% — EPS $0.21 vs $0.1818 estimate

Q4-2025: Beat consensus by 131.0% — EPS $0.07 vs $0.0303 estimate

Q4-2019: Beat consensus by 37.0% — EPS $-192000 vs $-304616 estimate

Q3-2025: Missed consensus by 94.8% — EPS $-0.31 vs $-0.1591 estimate

Q2-2025: Missed consensus by 26.0% — EPS $-0.176 vs $-0.1397 estimate

Q1-2026: Beat consensus by 15.1% — EPS $-0.2 vs $-0.2357 estimate

Q4-2025: Beat consensus by 37.9% — EPS $-0.22 vs $-0.3545 estimate

Q3-2025: Beat consensus by 26.1% — EPS $-0.69 vs $-0.9343 estimate

Q2-2025: Beat consensus by 21.6% — EPS $-3.47 vs $-4.4248 estimate

Q1-2026: Beat consensus by 21.6% — EPS $-0.16 vs $-0.204 estimate

Q3-2025: Missed consensus by 100.0% — EPS $0 vs $0.0041 estimate

Q2-2025: Beat consensus by 64.4% — EPS $-0.01 vs $-0.0281 estimate

Q1-2026: Beat consensus by 217.6% — EPS $0.01 vs $-0.0085 estimate

Q4-2025: Beat consensus by 33.6% — EPS $0.06 vs $0.0449 estimate

Q2-2025: Missed consensus by 5.8% — EPS $-1.07 vs $-1.0111 estimate

Q4-2025: Missed consensus by 7.8% — EPS $-1.31 vs $-1.2153 estimate

Q2-2025: Beat consensus by 27.5% — EPS $-0.37 vs $-0.51 estimate

Q3-2025: Beat consensus by 53.1% — EPS $-0.34 vs $-0.7242 estimate

Q4-2025: Beat consensus by 36.0% — EPS $-0.32 vs $-0.4998 estimate

Q1-2026: Beat consensus by 14.2% — EPS $-0.42 vs $-0.4896 estimate

Q2-2025: Beat consensus by 14.7% — EPS $0.75 vs $0.654 estimate

Q3-2025: Missed consensus by 7.0% — EPS $1.24 vs $1.3329 estimate

Q1-2026: Missed consensus by 623.1% — EPS $-0.41 vs $-0.0567 estimate

Q4-2021: Missed consensus by 5.0% — EPS $-22.5 vs $-21.42 estimate

Q2-2022: Missed consensus by 35.6% — EPS $-8.3 vs $-6.12 estimate

Q3-2021: Missed consensus by 178.6% — EPS $-40.5 vs $-14.535 estimate

Q4-2025: Missed consensus by 51.0% — EPS $-0.14 vs $-0.0927 estimate

Q1-2026: Beat consensus by 119.4% — EPS $0.002 vs $-0.0103 estimate

Q3-2025: Beat consensus by 28.7% — EPS $0.26 vs $0.202 estimate

Q2-2025: Beat consensus by 43.8% — EPS $0.17 vs $0.1182 estimate

Q4-2025: Missed consensus by 66.6% — EPS $0.07 vs $0.2097 estimate

Q3-2025: Beat consensus by 58.1% — EPS $-0.22 vs $-0.5253 estimate

Q2-2025: Missed consensus by 126.2% — EPS $-0.6 vs $-0.2652 estimate

Q4-2025: Beat consensus by 33.4% — EPS $-0.37 vs $-0.5559 estimate

Q1-2026: Beat consensus by 8.0% — EPS $2.26 vs $2.0921 estimate

Q4-2025: Missed consensus by 8.5% — EPS $1.94 vs $2.1197 estimate

Q2-2025: Beat consensus by 18.2% — EPS $2.46 vs $2.0816 estimate

Q3-2025: Beat consensus by 7.4% — EPS $2.45 vs $2.282 estimate

ETH ETF inflow of $448M — institutional buying

BTC ETF inflow of $2798M — institutional buying

BTC open interest -42.7% — OI collapse

SOL open interest -71.0% — OI collapse

ETH open interest +214.5% — OI surge

ETH open interest +223.2% — OI surge

SOL open interest +248.0% — OI surge

BTC open interest +77.4% — OI surge

BTC open interest +76.3% — OI surge

SOL open interest +140.8% — OI surge

ETH open interest +233.4% — OI surge

BTC open interest -66.5% — OI collapse

ETH open interest -67.7% — OI collapse

SOL open interest -71.4% — OI collapse

SOL DEX volume/liquidity ratio elevated (2.00x): on-chain trade volume 2.00x liquidity